DF
RARE icon

Dunhill Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Dunhill Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34 Sell
1
-1
-50% -$23 ﹤0.01% 1691
2025
Q4 		$38 Buy
+2
New +$66 ﹤0.01% 1748

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Dunhill Financial's RARE Position: Q1 2026 in Review

Dunhill Financial reduced its Ultragenyx Pharmaceutical (RARE) stake by 50% in Q1 2026, selling an estimated $23 and leaving 1 share worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

Dunhill Financial first reported a position in RARE in Q4 2025 and has held it in 2 quarters since. The position peaked at $38 in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Dunhill Financial held 1 share of Ultragenyx Pharmaceutical worth $34 as of Q1 2026.
  • Dunhill Financial sold 1 Ultragenyx Pharmaceutical share in Q1 2026, an estimated $23.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #1691 holding.
  • Dunhill Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • Dunhill Financial's Ultragenyx Pharmaceutical position peaked at $38 in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.